Outside experts called the results important and promising but added the full data should be released for a complete analysis of how it worked in this clinical trial.

“The low cost and broad availability of this drug mean that there is potential for considerable clinical impact by including it as part of standard treatment,” Dr. Stephen Griffin, an associate professor of medicine at the U.K.’s University of Leeds, said in a statement. Griffin was not involved with the trial.

“Nevertheless, it will be important to assess how this important success might be further improved in order to increase patient survival, perhaps through the combination of low-dose dexamethasone with other inflammatory mediators, or with virus-targeted therapies, such as remdesivir,” Griffin said.

Remdesivir is the only other therapy that’s been shown in a clinical trial to help coronavirus patients. Results of that trial found that hospitalized patients who received the drug recovered more quickly and were able to be released from the hospital faster. It did not affect mortality, though.